A groundbreaking advancement in HIV prevention has emerged from two major clinical trials, demonstrating results that medical researchers describe as almost unprecedented. The drug Lenacapavir, administered as a subcutaneous injection twice per year, has shown extraordinary efficacy in preventing HIV transmission among thousands of trial participants.
The first trial, designated PURPOSE 1, tested the medication among 3,200 participants in Uganda and South Africa—countries with high HIV incidence rates. The results were remarkable: 100% efficacy, with not a single young woman in the trial contracting HIV during the study period.
Building on these findings, PURPOSE 2 expanded the research significantly, encompassing 5,000 participants across multiple countries and continents. The trial broadened its scope beyond young women to include men and individuals of all ages. This larger, more diverse study yielded similarly impressive results: a 99.9% reduction in infection rates.
Both trials were conducted as phase 3 clinical studies using randomized, double-blinded protocols. Rather than testing against a placebo, researchers compared Lenacapavir to the current standard of HIV prevention—daily pills known as Truvada or Descovy. While these existing medications also demonstrated 99.9% efficacy during their development, they require daily adherence to maintain protection.
The twice-yearly injection schedule offers significant practical advantages over daily medication regimens. Maintaining consistent daily pill-taking over months and years presents challenges for many individuals. The reduced frequency of the Lenacapavir injections substantially improves adherence potential.
Beyond convenience, the injection format addresses important social considerations. In regions where HIV prevalence is high and where male homosexuality remains illegal—such as Uganda—the visibility of taking a daily HIV-prevention pill can carry significant social stigma. The discreet nature of twice-yearly injections helps alleviate this burden for at-risk populations.
The superiority of the injection method became so evident during the trials that both PURPOSE studies were halted early for ethical reasons. Researchers conducted a 52-week follow-up period to screen for any HIV developments among participants.
Science Magazine recognized Lenacapavir as the Breakthrough of the Year in 2024. The Food and Drug Administration subsequently approved the medication for use in humans under the brand name Yeztugo.
The drug operates through a sophisticated mechanism targeting the HIV virus's capsid shell. Lenacapavir binds to a highly conserved protein on the exterior of the virus—a protein that remains constant regardless of viral mutations. This targeting strategy ensures the drug remains effective even as the virus evolves.
Once bound to this protein, Lenacapavir disrupts the capsid shell, which the virus assembles and disassembles multiple times during its lifecycle with geometric precision. By interfering with this process, the drug prevents the virus from completing its replication cycle.
The development of Lenacapavir by Gilead Sciences required substantial investment. While the company has not disclosed exact figures, the costs associated with research and development, regulatory compliance, and proof of efficacy and safety likely exceeded one billion dollars—typical for pharmaceutical development of this magnitude.
Despite these development costs, Gilead Sciences has committed to providing the medication at cost in certain low-income regions. The company has licensed generic manufacturers to produce Lenacapavir for approximately $40 per year in 120 low and middle-income countries, with distribution scheduled to begin in 2027.
This pricing commitment represents a significant step toward making the breakthrough treatment accessible to populations most affected by HIV. The combination of extraordinary efficacy, improved adherence potential, and planned affordable access positions Lenacapavir as a transformative tool in global HIV prevention efforts.
